Recent Updates | November 2026

Recent Updates_November_2026

Here are a few NEET-PG-related, clinically important updates from recent months. 

Contents:

  1. Rusfertide: 1st-in-class FDA-approved drug for polycythemia vera
  2. AHA/ACC recommendations for patients with atrial fibrillation (2026)
  3. AHA 2026 Guidelines for Infective Endocarditis
  4. WHO 2026 guidelines on Malaria
  5. ESC criteria for the diagnosis of Cardiogenic Shock (2026)
  6. Rete ovarii: Reconsidering its role in ovarian function
  7. Rome V criteria for DGBIs

The FDA has approved rusfertide, a first-in-class hepcidin mimetic, for erythrocytosis in adults with polycythemia vera (PV).

MOA:

  • Blocks ferroportin (iron transporter).
  • Reduces iron availability for RBC production.
  • Lowers hematocrit levels, reducing blood viscosity.

Dose: Starting dose: 19 mg weekly SC; maximum: 108 mg weekly.

Adverse effects: Thrombocytosis, anaemia and injection-site reactions.

Contraindications: Pregnancy (embryo-fetal toxicity), breastfeeding and paediatric age groups.


AHA/ACC have updated clinical performance and quality measures for atrial fibrillation (AF).

Stroke prophylaxis:

  • Risk assessment: CHA₂DS₂-VASc, ATRIA or GARFIELD-AF.
  • Initiate anticoagulation if annual stroke risk is >2%.

Safer use of blood thinners:

  • AF Post-PCI: Discontinue aspirin within 1- 4 weeks; prefer DOAC + P2Y12 inhibitor over triple therapy.
  • AF with chronic coronary disease: Prefer anticoagulation monotherapy.

Other recommendations:

  • Newly diagnosed AF: Transthoracic echocardiogram, CBC and TSH.
  • Lifestyle changes: ≥10% weight loss, 210 minutes/week of moderate-to-vigorous exercise, quit smoking and regular alcohol intake.
  • Dofetilide initiation/dose escalation: Only during a 3-day hospital stay.

AHA has updated its guidelines for diagnosis and management of infective endocarditis.

Diagnosis:

  • Adopts 2023 Duke/ISCVID criteria, replacing 2000 modified Duke criteria.
  • Enterococcus faecalis is now considered a typical IE pathogen, regardless of whether it is community-acquired or associated with a known primary focus.
  • Blood collection for culture is simplified by removing the strict timing and separate-venipuncture-site rules.

Antibiotic regimen updates:

  • Staphylococcal PVE: Gentamicin not recommended.
  • Staphylococcal NVE: Postoperative monotherapy preferred.
  • Streptococci/ S. gallolyticus: Ceftriaxone monotherapy for penicillin-intermediate strains if 3rd-generation cephalosporin MIC ≤0.5 mg/L.
  • Left-sided IE: Partial oral therapy after ≥10 days of IV therapy.

Other updates: Complete CIED extraction preferred; colonoscopy for all patients with E. faecalis/S. gallolyticus IE and percutaneous mechanical aspiration when surgery is risky.


WHO has updated four major recommendations for malaria prevention and management.

Key updates:

  • HIV-positive pregnant women: Dihydroartemisinin-piperaquine may be used if local malaria resistance is high and is compatible with HIV medication. Sulfadoxine-pyrimethamine is contraindicated with co-trimoxazole.
  • Low-transmission areas: Primaquine 0.25 mg/kg single dose with ACT for P. falciparum. G6PD testing is not mandatory. Excludes pregnancy, infants <1 month and breastfeeding women with infants <1 month.
  • Infants <5 kg: In uncomplicated P. falciparum malaria, ACT at the same mg/kg target dose as infants >5 kg. Prefer artemether-lumefantrine (1:12 ratio) designed specifically for infants <5 kg, if available.
  • Vaccination: First dose can be given before 5 months. Three doses benefit children in vulnerable settings if the fourth dose cannot be delivered.

ESC has introduced standardised diagnostic criteria for cardiogenic shock. All three parameters must be fulfilled, along with suggestive clinical and point-of-care assessments.

1. Cardiac dysfunction:

  • Severe LV/RV/biventricular dysfunction, severe valvular disease or mechanical complications.
  • Recurrent/persistent ventricular arrhythmias.
  • Exclude obstructive shock.

2. Haemodynamic abnormality: ≥2 of:

  • SBP <90 and/ or MAP <65 mmHg for >30 min.
  • SBP ≥90 and/ or MAP ≥65 mmHg on vasoactive drugs.
  • Raised filling pressures.
  • Cardiac index <2.2 L/min/m² without vasoactive drugs.

3. Hypoperfusion: ≥1 clinical sign AND ≥1 metabolic parameter.


The rete ovarii (RO), previously considered a functionless vestigial structure, is being reconsidered as a potentially functional organ and the female homologue of the rete testis.

Development: Arises from mesonephric tubules and persists into adulthood.

Anatomy: A network of epithelial cells and tubules attached to the ovarian hilum, comprising:

  • Extraovarian rete: Columnar epithelial cells.
  • Connecting rete: Pseudocolumnar cells.
  • Intraovarian rete: Squamous epithelial cells forming branching networks of thin cell cords.

Function: Secretory material within its tubules and experimental findings suggest that RO sends material to the ovary and may contribute to ovarian function.


The Rome Foundation has released Rome V criteria, 10 years after Rome IV (2016). Key changes include updated terminology, revised IBS diagnostic criteria and a shift towards positive diagnostic approach rather than diagnosis of exclusion.

Terminology updates:

  • Functional GI disorders → Disorders of gut-brain interaction (DGBIs).
  • Functional constipation → Chronic constipation.
  • Functional nausea → Chronic nausea syndrome.
  • Unspecified bowel disorder → Unclassified bowel disorder.

Updated IBS criteria: Recurrent abdominal pain/discomfort ≥3 days/month in the last 3 months, with ≥2 features:

  • Relation to defecation
  • Associated with a change in stool frequency
  • Associated with a change in stool form (appearance)

Clinical diagnosis is possible after 8 weeks if symptoms are bothersome.

New disorders: Inability to belch syndrome, abdominal migraine and anorectal sensory dysfunction disorder.

Management: Mild: education & referral to a dietitian; moderate: behavioural therapy and pharmacotherapy; severe: central neuromodulators and specialist referral.

To see the complete list of updates, check out the Recent Updates section on your Marrow app.

Share

Leave a Reply

Your email address will not be published. Required fields are marked *